Genmab (GMAB) said Monday it is discontinuing further clinical development of tumor treatment acasunlimab to focus on programs with the "highest potential impact."
The company said it will focus on Epkinkly, petosemtamab, and Rina-S, which are advancing in late-stage development.
Genmab said the move does not impact its full-year 2025 financial guidance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments